AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28882117
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire regarding eye diseases awareness and practices
Trial: 28882349
Drug: Titanium clip-screw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium clip-screw implant system
Trial: 28882565
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium absorption study
Trial: 28883932
Drug: 1000 international
RxNorm normalized name: Sundance Vitamin D3 1000 International Units Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 international units per day of oral vitamin D
Trial: 28884840
Drug: Hydroxycarbamide (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxycarbamide (first dose)
Trial: 28884840
Drug: Hydroxycarbamide (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxycarbamide (chronic therapy)
Trial: 28886760
Drug: Transcranial Magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Magnetic Stimulation (TMS) at 5 Hz, delivered in up to 40 daily sessions to the left dorsolateral prefrontal cortex
Trial: 28887375
Drug: Initial IVH
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial IVH volume exceeding 20 mL
Trial: 28887751
Drug: Drug-Using, Violence-Exposed,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Using, Violence-Exposed, and Impaired Sex class (n = 53; 14%)
Trial: 28889107
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from phosphodiesterase-5 inhibitors (PDE5i) to riociguat
Trial: 28889769
Drug: Orsiro biodegradable
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orsiro biodegradable polymer drug-eluting stent (BP-DES)
Trial: 28889769
Drug: Xience durable
RxNorm normalized name: Ruxience
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xience durable polymer drug-eluting stent (DP-DES)
Trial: 28893779
Drug: Ceftolozane-tazobactam 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane-tazobactam 1.5 g every 8 hours (q8h)
Trial: 28894606
Drug: Conventional maximum
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional maximum treatment (control)
Trial: 28898890
Drug: Pirfenidone, mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone, mean daily dose of 2,091.1 mg, mean exposure of 122 weeks (SD 98), median exposure of 88 weeks (range >0 to 349 weeks)
Trial: 28899363
Drug: LJM716 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJM716 40 mg/kg QW
Trial: 28899517
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of OSA
Trial: 28899517
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment of OSA
Trial: 28900040
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid nebulization (2.8 mol/L)
Trial: 28900714
Drug: peginterferon alpha-2a
RxNorm normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24-72 weeks
Trial: 28902596
Drug: Investigational assay
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational assay for detecting resistance to moxifloxacin at 0.5 μg/mL
Trial: 28902596
Drug: Investigational assay
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational assay for detecting resistance to moxifloxacin at 2.0 μg/mL
Trial: 28903943
Drug: SGN-CD19B at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-CD19B at a dose of 300 μg/kg (3 μg/kg drug equivalents)
Trial: 28903943
Drug: SGN-CD19B in
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-CD19B in combination with rituximab at a dose of 100 μg/kg (1 μg/kg drug equivalents)
Trial: 28905294
Drug: Methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate cream (MAL) daylight photodynamic therapy (DL-PDT)
Trial: 28905323
Drug: 5-azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-azacitidine (75 mg/m²)
Trial: 28911136
Drug: Pork ingestion
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork ingestion (170 g) in the OB group
Trial: 28911136
Drug: Pork ingestion
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork ingestion (170 g) in the NW group
Trial: 28911136
Drug: Pork ingestion
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork ingestion (170 g) in the OW group
Trial: 28911922
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg q12h daily combined with gemcitabine and cisplatin (SGC)
Trial: 28912376
Drug: BAX 930
RxNorm normalized name: BAX 855
DrugBank: Rurioctocog alfa pegol (DB16007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX 930 (recombinant ADAMTS-13) at doses of 5, 20, or 40 U/kg body weight
Trial: 28912629
Drug: Multiple spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple spinal manipulations administered in a single session
Trial: 28913922
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at maximal tolerated dose (MTD)
Trial: 28916953
Drug: 30-mg dexlansoprazole
RxNorm normalized name: dexlansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg dexlansoprazole
Trial: 28917612
Drug: Thyroid-stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid-stimulating hormone level >2.5 mIU/L
Trial: 28917612
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of thyroid antibodies
Trial: 28917648
Drug: Fluoropyrimidine/bevacizumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer
Trial: 28917673
Drug: hsTnT ≥15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsTnT ≥15 ng/l (n=29) in Group B
Trial: 28917673
Drug: BNP ≥550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP ≥550 pg/ml (n=10) in Group B
Trial: 28918167
Drug: Low muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low muscle mass in combination with low strength
Trial: 28919031
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) injection for fluorescence detection of sentinel lymph nodes (SLN)
Trial: 28919454
Drug: Abagovomab (anti-idiotypic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination
Trial: 28919776
Drug: Omaveloxolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omaveloxolone (15 mg orally once daily)
Trial: 28921872
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg/day, orally, continuously
Trial: 28922088
Drug: Perfluorohexyloctane, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfluorohexyloctane, 1 drop, 4 times daily for 6-8 weeks
Trial: 28922337
Drug: Daily use
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily use of the web
Trial: 28922466
Drug: Blinatumomab (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (continuous intravenous infusion)
Trial: 28923060
Drug: Vitamin-D deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-D deficiency (<10 ng/ml)
Trial: 28923104
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of enadenotucirev
Trial: 28923104
Drug: Intratumoral (IT)
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral (IT) injection of enadenotucirev (CRC only)
Trial: 28923290
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of Kaletra (lopinavir/ritonavir)
Trial: 28924018
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg daily until cGVHD progression)
Trial: 28925027
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) drug levels <200 ng/ml or undetectable desethylchloroquine
Trial: 28925027
Drug: Self-administered questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaires (MASRI <80% or MMAS-8 <6)
Trial: 28925785
Drug: Fludarabine, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy after four cycles (FCR4)
Trial: 28925785
Drug: Fludarabine, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy at end of treatment (EOT)
Trial: 28925785
Drug: Fludarabine, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy
Trial: 28926513
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg phytoSERM
Trial: 28926513
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg phytoSERM
Trial: 28927372
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate regular medication
Trial: 28927372
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more potentially inappropriate medications
Trial: 28927372
Drug: Medication needing
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication needing surveillance according to NORGEP-NH
Trial: 28927372
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of psychotropic drugs
Trial: 28927372
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate regular medication (females)
Trial: 28927372
Drug: Three or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more concomitant psychotropic medications (females)
Trial: 28927372
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of multiple psychoactive drugs
Trial: 28928173
Drug: First-line anti-TB
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-TB treatment
Trial: 28928706
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical treatments
Trial: 28928789
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicine (CAM) treatment during hospitalization
Trial: 28931498
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular colonoscopy preparation leaflet)
Trial: 28932269
Drug: IBS-D Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBS-D Daily Symptom Diary and Event Log
Trial: 28932270
Drug: Open-label rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label rifaximin 550 mg three times daily for 2 weeks
Trial: 28932928
Drug: Single 4.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 4.1 mg oral solution dose of ixazomib
Trial: 28933971
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 200 mcg
Trial: 28933971
Drug: FS MDPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS MDPI 200/12.5 mcg
Trial: 28933971
Drug: Fp DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fp DPI 500 mcg (250 mcg × 2 inhalations)
Trial: 28933971
Drug: FS DPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS DPI 500/50 mcg
Trial: 28934680
Drug: Gandotinib (LY2784544),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gandotinib (LY2784544), a potent inhibitor of JAK2 activity
Trial: 28935432
Drug: ravidasvir 200
RxNorm normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks (with or without ribavirin)
Trial: 28935452
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (median 4 months, range 2-24 months)
Trial: 28935718
Drug: Cooling therapy
RxNorm normalized name: MENTHOL 2.8 g in 56 g TOPICAL CREAM [elevate COOLING THERAPY TWIST UP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling therapy (prematurely discontinued)
Trial: 28936121
Drug: Education intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Education intervention consisting of a two-day seminar and monthly coaching sessions for six months.
Trial: 28936626
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not receiving specific ICU procedures (ventilation, vasoactive drugs, renal replacement therapy)
Trial: 28936952
Drug: Injection test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection test with esophageal balloon catheter
Trial: 28938419
Drug: Urinary concentrations
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary concentrations of LH after 3 months of GnRH treatment
Trial: 28938918
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) at dose level 3 (36 Gy/3)
Trial: 28938918
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) in combination with pazopanib
Trial: 28939546
Drug: Smart technology
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart technology intervention (daily measurements with smartphone-compatible ECG device, BP monitor, weight scale, activity tracker; two electronic visits)
Trial: 28941036
Drug: SUMO4 rs237025
RxNorm normalized name: Sumox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUMO4 rs237025 G allele
Trial: 28941623
Drug: MenACWY-D vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-D vaccine
Trial: 28944067
Drug: Probiotic intervention
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic intervention (two daily tablets totalling 1.4×10)
Trial: 28944714
Drug: Gymnemic acids
RxNorm normalized name: GYMNEMA SYLVESTRIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gymnemic acids (GA) lozenge
Trial: 28945848
Drug: Panitumumab in
RxNorm normalized name: panitumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab in combination with irinotecan
Trial: 28945911
Drug: E/C/F/TDF therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TDF therapy, no LXR agonist
Trial: 28945911
Drug: E/C/F/TDF therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TDF therapy, LXR agonist
Trial: 28945911
Drug: Non-HIV-infected subjects,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HIV-infected subjects, no LXR agonist
Trial: 28945911
Drug: Non-HIV-infected subjects,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HIV-infected subjects, LXR agonist
Trial: 28946874
Drug: Periurethral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periurethral injection of autologous regenerative cells from adipose tissue using the Celution® system
Trial: 28948137
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention to promote colorectal cancer (CRC) screening; specific details on dosage and duration not available.
Trial: 28948137
Drug: Implementation strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation strategies for the evidence-based intervention; specific details on dosage and duration not available.
Trial: 28948656
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aliskiren and Enalapril
Trial: 28950146
Drug: Buparlisib 80
RxNorm normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 80 mg/d + Lapatinib 1000 mg/d
Trial: 28950146
Drug: Buparlisib 40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib 40, 60, or 80 mg + Lapatinib 750, 1000, or 1250 mg
Trial: 28950288
Drug: selumetinib 50
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 50 or 75 mg plus gemcitabine/cisplatin (n=10)
Trial: 28950288
Drug: selumetinib 50
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 50 mg plus gemcitabine/carboplatin (n=9)
Trial: 28950288
Drug: selumetinib 100
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 100 mg plus pemetrexed/carboplatin (n=21)
Trial: 28950288
Drug: selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 75 mg plus pemetrexed/cisplatin (n=15)
Trial: 28950288
Drug: selumetinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selumetinib (various doses) plus chemotherapy
Trial: 28950288
Drug: selumetinib plus
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib plus chemotherapy
Trial: 28950288
Drug: selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selumetinib 75 mg BID with standard doses of pemetrexed/carboplatin or pemetrexed/cisplatin
Trial: 28950298
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg i.v. every 3 weeks until loss of clinical benefit
Trial: 28950298
Drug: Other systemic
RxNorm normalized name: Other systemic hemostatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other systemic therapy
Trial: 28950298
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further systemic therapy
Trial: 28950338
Drug: Afatinib (pan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (pan HER-family kinase inhibitor)
Trial: 28951336
Drug: Insulin-treated patients
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated patients with type 1 diabetes
Trial: 28951336
Drug: Insulin-treated patients
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated patients with type 2 diabetes
Trial: 28952191
Drug: STARD3 (hub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STARD3 (hub gene for energy metabolism module)
Trial: 28952191
Drug: G-protein coupled
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-protein coupled receptor protein signaling pathway
Trial: 28954285
Drug: Proton-based stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-based stereotactic body radiation therapy (SBRT) with a median dose of 40 GyE (range = 30-50 GyE) in five fractions.
Trial: 28956281
Drug: Autoinjector for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoinjector for self-administration of subcutaneous belimumab
Trial: 28956335
Drug: PDE inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDE inhibitors